Aditxt Acquires Ignite Proteomics Focused on Optimizing Therapy Selection

Aditxt Co-Founder and Chief Executive Officer Amro Albanna stated: “Each year nearly 20 million people are diagnosed with cancer worldwide, tens of millions undergo treatment, and millions of patients with advanced disease ultimately face limited therapeutic options. These realities underscore the importance of improving how therapies are selected, particularly as precision medicines increasingly depend on identifying whether a patient’s tumor expresses the intended biological targets for those therapies. We believe there is a real need for tools that can provide physicians with additional information to help support more informed treatment decisions, particularly as targeted therapies become more precise and more complex.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib